Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Midamor

(amiloride)

ApprovedSmall molecule

Amiloride is a water pill used to treat high blood pressure and heart failure. Unlike other diuretics, it helps the body eliminate excess water and salt while preserving potassium, making it especially useful for patients who are at risk of having too-low potassium levels.[2] Midamor is currently approved and in use across 20 indications[4].[1]

Midamor is one of 504 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

20

Indications

34

Total Trials

4

Active Trials

503

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Attention Deficit Hyperactivity DisorderApproved

Kidney DiseaseActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Congestive Heart FailureActive, not recruiting

HypertensionApproved

ProteinuriaActive, not recruiting

Primary HyperparathyroidismActive, not recruiting

Breast CancerActive, not recruiting

Coronary Artery DiseasePhase 2

Active, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Attention Deficit Hyperactivity DisorderApproved

Approved

Kidney DiseasePhase 2

Active, not recruiting

Nephrotic SyndromePhase 3

Active, not recruiting

Congestive Heart FailureApproved

Active, not recruiting

HypertensionApproved

Approved

ProteinuriaApproved

Active, not recruiting

Primary HyperparathyroidismPhase 2/Phase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Midamor

Halaven

Cymbalta

Alnylam Pharmaceuticals

MS Contin

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Feraheme

AAzurity Pharmaceuticals

Apatinib Mesylate

BBukwang Pharmaceutical

Fentanyl Citrate

IINSYS Therapeutics Inc

Motexafin Gadolinium

PPharmacyclics LLC.

Metfomin

UUniversity of Texas Southwestern Medical Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Heart Failure

NCT05753059

Q4 2027

Phase 2Recruiting

Migraine

NCT04063540

Q2 2029

Phase 2Not yet recruiting

Breast Cancer

NCT06224673

Clinical

Trials by Indication[1]

Hypertension9 trials

Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension

Withdrawn·VVA Salt Lake City Health Care System·N/A·NCT00709137

Comparison of Single and Combination Diuretics in Low-Renin Hypertension

Unknown status·UUniversity of Cambridge·Phase 4·NCT02351973·423 enrolled

The Effect of Amiloride and Spironolactone in Patients With Hypertension

Completed·EErling Bjerregaard Pedersen·Phase 4·NCT01388088·23 enrolled

Show 6 more trials

Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension

Unknown status·—·Phase 4·NCT01308983·32 enrolled

Comparison of Optimal Hypertension Regimens

Completed·—·Phase 4·NCT02847338·940 enrolled

Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension

Completed·YYonsei University·Phase 4·NCT04331691·118 enrolled

Amiloride for Resistant Hypertension

Completed·IIb Abildgaard Jacobsen·Phase 4·NCT02122731·80 enrolled

Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension

Completed·SSao Jose do Rio Preto Medical School·Phase 4·NCT02832973·72 enrolled

Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 3·NCT03928145·84 enrolled

Chronic Kidney Disease3 trials

A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein

Completed·GGuangdong Provincial People's Hospital·Phase 4·NCT03170336·40 enrolled

Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease

Recruiting·OOdense University Hospital·Phase 2·NCT06923709·40 enrolled

DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease

Completed·EErasmus Medical Center·Phase 4·NCT02875886·28 enrolled

Kidney Disease2 trials

Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease

Unknown status·UUniversity of Southern Denmark·N/A·NCT01918488·80 enrolled

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02497300·21 enrolled

Primary Hyperparathyroidism1 trial

Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism

Completed·—·Phase 2/3·NCT02525796·69 enrolled

Coronary Artery Disease1 trial

Novel Treatment for Coronary Artery Disease

Unknown status·UUniversity of Carabobo·Phase 2/3·NCT01228214·100 enrolled

18 more indications

Type 2 Diabetes1 trial

Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes

Terminated·UUniversity of New Mexico·Phase 1·NCT01804777·9 enrolled

Heart Failure1 trial

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

Recruiting·YYale University·Phase 1·NCT05753059·50 enrolled

Proteinuria1 trial

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

Unknown status·GGeorgetown University·Phase 4·NCT02522650·30 enrolled

Heart Disease1 trial

Treatment of Coronary Heart Disease With Amiloride

Completed·UUniversity of Carabobo·Phase 2/3·NCT01231165·70 enrolled

Spironolactone1 trial

The Effect of Amiloride and Spironolactone in Healthy Persons

Completed·RRegional Hospital Holstebro·Phase 1·NCT00857909·30 enrolled

Heartburn1 trial

Do Acid Sensing Ion Channels Contribute to Heartburn?

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT01095133·24 enrolled

Microcirculation1 trial

Microcirculation & ASICs

Completed·HHospices Civils de Lyon·N/A·NCT01246180·20 enrolled

Cystic Fibrosis1 trial

Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004705

Treatment1 trial

Amiloride Hydrochloride as an Effective Treatment for ADHD

Terminated·SState University of New York - Upstate Medical University·Phase 1·NCT01733680·3 enrolled

Nephrotic Syndrome1 trial

Amiloride in Nephrotic Syndrome

Terminated·UUniversity Hospital Tuebingen·Phase 3·NCT05079789·20 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene

Completed·—··NCT05125237·155,963 enrolled

Cardiovascular1 trial

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

Completed·RRegional Hospital Holstebro·N/A·NCT01195805·25 enrolled

Migraine1 trial

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Recruiting·—·Phase 2·NCT04063540·40 enrolled

Optic Neuritis1 trial

Amiloride Clinical Trial In Optic Neuritis

Completed·UUniversity of Oxford·Phase 2·NCT01802489·46 enrolled

Tics1 trial

Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers

Completed·UUniversity of Utah·Phase 1·NCT04181008·15 enrolled

Multiple Sclerosis1 trial

MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

Completed·UUniversity College, London·Phase 2·NCT01910259·445 enrolled

Breast Cancer1 trial

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Not yet recruiting·LLaura Huppert, MD, BA·Phase 2·NCT06224673·36 enrolled

Unspecified1 trial

Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant

Completed·OOspedale San Raffaele·Phase 3·NCT06416735·40 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

MIDAMOR

NDA NDA018200

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for amiloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Midamor drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — amiloride compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for amiloride. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA018200). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Padagis LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Amiloride-Sensitive Sodium Channel, Enac Blocker[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPadagis LLC

Related News